Novavax (NVAX) Misses Q4 EPS, Revenues; Provides Vaccine Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
March 1, 2021 4:02 PM EST96% vaccine efficacy against original COVID-19 in UK Phase 3 trialVaccine cross-protection demonstrated against both variants circulating in the UK and South AfricaFull enrollment (~30,000 participants) in PREVENT-19 Phase 3 trialAgreements for ~300 million doses to dateAdditional 1.1 billion doses to be supplied to the COVAX Facility (jointly with Serum Institute of India)Clinical trial of variant strain vaccines as standalone and bivalent candidates expected mid-2021Company to host conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc.... More
